Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Aim: to observe the graft versus tumor effect of Pegylated Interferonα-2b in patients with
hematological malignancies relapsed after allogeneic hematopoietic stem cell transplantation
(alloHSCT) Patients: patients relapsed after alloHSCT, men and women aged 14-60 years,
without vital organ dysfunction or ongoing graft-verus-host disease (GVHD).
Number of subjects: 50, Single center, one group, prospective. Drug: pegylated interferon
alpha-2b (Peg Intron®; Schering-Plough) 1~1.5ug/kg qw, until occurrence of grade II or higher
grade of acute GVHD, or no response to treatment after 8 doses of treatments.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine